Intermittent Hypoxia in Persons With Multiple Sclerosis

Description

This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.

Conditions

Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive

Study Overview

Study Details

Study overview

This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.

Intermittent Hypoxia Initiated Motor Plasticity in Individuals With Multiple Sclerosis

Intermittent Hypoxia in Persons With Multiple Sclerosis

Condition
Multiple Sclerosis
Intervention / Treatment

-

Contacts and Locations

Chicago

Shirley Ryan AbilityLab, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)
  • * Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
  • * Motor Functional System Scale (FSS) between 2-4
  • * Relapse free for at least 1 year
  • * Age ≥ 18 years and ≤ 75 years
  • * Safe to be scanned based on MRI questionnaire
  • * Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
  • * Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan
  • * Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)
  • * History of epilepsy
  • * Chronic obstructive pulmonary disease
  • * Uncontrolled Sleep apnea
  • * Pregnancy

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Shirley Ryan AbilityLab,

Milap Sandhu, Pt, PhD, PRINCIPAL_INVESTIGATOR, Shirley Ryan AbilityLab

Study Record Dates

2027-01